Jacobs Levy Equity Management, Inc Regenxbio Inc. Transaction History
Jacobs Levy Equity Management, Inc
- $24.7 Billion
- Q3 2024
A detailed history of Jacobs Levy Equity Management, Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 89,218 shares of RGNX stock, worth $993,888. This represents 0.0% of its overall portfolio holdings.
Number of Shares
89,218
Previous 152,437
41.47%
Holding current value
$993,888
Previous $1.78 Million
47.56%
% of portfolio
0.0%
Previous 0.01%
Shares
17 transactions
Others Institutions Holding RGNX
# of Institutions
198Shares Held
43.2MCall Options Held
104KPut Options Held
478K-
Black Rock Inc. New York, NY8.61MShares$95.9 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.89MShares$54.5 Million3.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.37MShares$48.7 Million0.0% of portfolio
-
State Street Corp Boston, MA2.78MShares$31 Million0.0% of portfolio
-
Jpmorgan Chase & CO New York, NY2.48MShares$27.6 Million0.0% of portfolio
About REGENXBIO Inc.
- Ticker RGNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 43,230,000
- Market Cap $482M
- Description
- REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...